Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 4/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 3/20 | 0.51 |
| ▸ | KIT | P10721 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217584 | 0.88 | MAPK14 (0.64) | MAPK14MAPK11LCKKITKDR | |
| SCHEMBL2216662 | 0.82 | KHK (0.57) | KHKMAPK14MAPK11LCKKIT | |
| SCHEMBL2216631 | 0.81 | MAPK14 (0.54) | KHKMAPK14MAPK11MAPKAPK2MAPK13 | |
| SCHEMBL5567280 | 0.78 | KHK (0.55) | KHKMAPK14MAPK11LCKKIT | |
| SCHEMBL4229997 | 0.74 | NR3C1 (0.58) | MAPK14MAPK11LCKKITKDR | |
| SCHEMBL4219336 | 0.71 | HPGDS (0.55) | KHKMAPK14MAPK13HPGDS | |
| SCHEMBL2214290 | 0.71 | MAPK14 (0.54) | KHKMAPK14MAPK11LCKKIT | |
| SCHEMBL3523058 | 0.71 | MAPK14 (0.56) | MAPK14LCKKITKDRMAPK13 | |
| SCHEMBL4219489 | 0.71 | NR3C1 (0.56) | MAPK14MAPK11LCKKITKDR | |
| SCHEMBL3520197 | 0.70 | MAPK14 (0.60) | MAPK14LCKKITKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | KHK 2805/4885MAPK14 14/4885MAPK11 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.